b.value AG

Investing in the core technologies of the future - for real innovations in fast-growing markets

b.value AG

Impact by Deep Tech

We invest in deep tech startups with exceptional founders and breakthrough technologies that offer solutions for a sustainable tomorrow.

As core technologies, biotechnology and new materials are key enablers of sustainable processes and products as the foundation of tomorrow's world. Therefore, b.value AG invests in talented and courageous entrepreneurs who want to build the companies of the future with highly scalable business models and, disruptive and proprietary biotechnology and material technology based innovations. Our unique fund structure and our operative experience allow us to act flexibly and for the long term.

Investment-Fokus

Our world is transforming and with it the industries. With biotechnology (including precision fermentation, sustainable chemicals, food/feed, life science tools) and advanced materials as b.value’s investment focus, we address future markets of the future that are characterized by above-average growth.

Goals

Our goal is to build a future-oriented portfolio of fast-growing, deep tech start-up companies that define the production processes and markets of the future. In doing so, we bridge the gap from research and development to global markets. Our specialization, deep market and industry understanding as well as our operational experience are the key to success - for our portfolio companies and investors alike.

Investment focus

We invest within the D-A-CH region in pre-seed and seed stage companies whose products or business models address the future markets of biotechnology and advanced materials. We acquire minority stakes and invest together with other co-investors.

Entrepreneurial experience in building successful biotech and high tech companies

Support from experts with exceptional technology understanding

Extensive network of experienced supervisory board members, scientists, executives, investors, political decision-makers, and industrial and academic thought leaders

Unique opportunity in Germany to participate in future biotechnology and advanced materials companies at a very early stage of development

For a sustainable world of tomorrow

Investment Portfolio

b.value Team

A partnership of equals

We know from first hand experience, what matters to founders!

25 years of entrepreneurial experience as a founder, scaling expert and investor underpinned by an extensive track record is the basis of our proactive support - from founders for founders.

Support by a team of experts with an exceptional understanding of technology

The profound knowledge of our operational team, consisting of scientists with doctorates in various fields, builds partnerships with the founders on an equal footing and enables a technology assessment that goes beyond the usual and looks "under the hood".

Peter

Dipl.-Kfm. Peter Kallien

Managing Director

MBA
20+ years of experience as managing director/board member in science, biotech and life science

Georg

Dr. Georg Lentzen

Managing Director

Biochemist
20+ years of experience in leading positions in the biotech industry in Germany, GB, NL

Cornelia

Dr. Cornelia Bähr

Senior Investment Manager

Bioprocess engineer
10 years of experience bioprocess development, 8 years consulting experience in the biotech/chemical industry

Pelin

Dr. Pelin Yilmaz

Senior Investment Manager

Bioinformatician/Microbiologist
10 years of international experience in bioinformatics, AI and microbiome research

Marie

M.Sc. Marie Kappen

Investment Manager

Nanotechnologist/Biophysicist
Interdisciplinary expertise in nanotechnology and biotechnology

Supervisory Board

Experienced, successful, well-connected

b.value benefits from the supervisory board's many years of industry, transaction and IPO experience

Prof. Dr. Manfred Niewiarra

Jurist, Vorsitzender des Ausichtsrates
  • former Head of M&A
  • Bertelsmann AG &
    Member of the Executive Board Axel Springer AG,
  • Member of the Board CLT UFA

Prof. Dr. Michael Dröscher

Chemist
  • Former Managing Director Evonik Creavis GmbH
  • President of GdCh
  • Member of the Board of Trustees of MPI-P (Mainz) and LIKAT (Rostock)

Dr. Jürgen Eck

Biotechnologist, Entrepreneur, Innovator, Investor
  • CTO and Co-CEO SymbioPharm
  • Co-Founder & former CEO of B.R.A.I.N AG
  • Member of the Board of BIO Germany and DECHEMA

Dr. Dahai Yu

Chemist
  • Chairman of the Supervisory Board of Röhm and Caldic
  • Member of the supervisory boards of Sinochem International, allnex and GETEC,
  • Former member of the Executive Board of Evonik Industries AG
  • Operating Partner for Advent International
  • Corporate Advisor for Temasek International

News

you can find more news on our LinkedIn page

09.12.2022

Congratulations on the New Economy Award 2022 

Last Friday, 02.12.2022, CEO Anne Lang received the Next Economy Award 2022 in behave of the whole traceless team. The Next Economy Award (NEA) is the startup competition of the German Sustainability Award (Deutscher Nachhaltigkeitspreis) - Europe's leading award for ecological and social engagement. The NEA prizes founders who drive social and ecological change with innovative business models, and is awarded in cooperation with Evonik Industries. Traceless is one of three winning startups elected through a public voting. Congratulations to the whole traceless team – well deserved for your continuous engagement to make the world a better place! More information and pictures at https://www.traceless.eu/post/traceless-is-one-of-the-next-economy-award-winners  

First traceless® product hits C&A shelves 

Traceless‘s vision is to remove more and more products of our daily live by sustainable alternatives made of the traceless® granulate. Therefore, we are very proud that the company published its collaboration with the fashion retailer C&A yesterday. First pilot product are traceless® sock-hooks. On the 8th of December the product was launched in the C&A Store in Hamburg Altona. We have already had the hooks in our hands and were very impressed.Looking forward to the next traceless® products! More information and impressions on the traceless® sock-hooks at https://www.traceless.eu/post/collaboration-with-c-a-first-traceless-product-hits-the-shelves. 

Congratulations on the New Economy Award 2022 

Last Friday, 02.12.2022, CEO Anne Lang received the Next Economy Award 2022 in behave of the whole traceless team. The Next Economy Award (NEA) is the startup competition of the German Sustainability Award (Deutscher Nachhaltigkeitspreis) - Europe's leading award for ecological and social engagement. The NEA prizes founders who drive social and ecological change with innovative business models, and is awarded in cooperation with Evonik Industries. Traceless is one of three winning startups elected through a public voting. Congratulations to the whole traceless team – well deserved for your continuous engagement to make the world a better place! More information and pictures at https://www.traceless.eu/post/traceless-is-one-of-the-next-economy-award-winners  

First traceless® product hits C&A shelves 

Traceless‘s vision is to remove more and more products of our daily live by sustainable alternatives made of the traceless® granulate. Therefore, we are very proud that the company published its collaboration with the fashion retailer C&A yesterday. First pilot product are traceless® sock-hooks. On the 8th of December the product was launched in the C&A Store in Hamburg Altona. We have already had the hooks in our hands and were very impressed.Looking forward to the next traceless® products! More information and impressions on the traceless® sock-hooks at https://www.traceless.eu/post/collaboration-with-c-a-first-traceless-product-hits-the-shelves. 

03.10.2022

Cellbricks GmbH wins this year's Spark Award, which is presented by McKinsey & Company and Handelsblatt. Cellbricks successfully competed in a highly qualified field of 750 medical technology start-ups. The renowned jury described Cellbricks' 3D bioprinting capabilities as a "quantum leap in medicine" and highlighted the scalability to replicate human tissue and print entire organs in the future.

Further information:

Artikel des Handelsblatts

LinkedIn – Cellbricks

 

 

Cellbricks GmbH wins this year's Spark Award, which is presented by McKinsey & Company and Handelsblatt. Cellbricks successfully competed in a highly qualified field of 750 medical technology start-ups. The renowned jury described Cellbricks' 3D bioprinting capabilities as a "quantum leap in medicine" and highlighted the scalability to replicate human tissue and print entire organs in the future.

Further information:

Artikel des Handelsblatts

LinkedIn – Cellbricks

 

 

13.09.2022

What an incredible news: The founders of our portfolio company traceless materials, Anne Lamp and Johanna Baare, have won the prestigious award Deutscher Gründerpreis 2022 (German Entrepreneur Award) last night. Congratulations!

These inspiring ladies and their team did a fantastic job over the last 18 months which has been honored by numerous awards - absolutely justified since they work hard for the vision to substitute 1 Mio t plastics until 2031. It is a great pleasure to be at your side together with our partners Johannes Weber at High-Tech GründerFonds as well as Tobias Seikel and Christian Schad at Planet A Ventures. It is an exciting journey with you! Looking forward to what is coming next!

What an incredible news: The founders of our portfolio company traceless materials, Anne Lamp and Johanna Baare, have won the prestigious award Deutscher Gründerpreis 2022 (German Entrepreneur Award) last night. Congratulations!

These inspiring ladies and their team did a fantastic job over the last 18 months which has been honored by numerous awards - absolutely justified since they work hard for the vision to substitute 1 Mio t plastics until 2031. It is a great pleasure to be at your side together with our partners Johannes Weber at High-Tech GründerFonds as well as Tobias Seikel and Christian Schad at Planet A Ventures. It is an exciting journey with you! Looking forward to what is coming next!

25.05.2022

Seed round for market entry of Revoltech GmbH's sustainable leather alternative LOVR.

Darmstadt, May 25, 2022 - Darmstadt-based startup Revoltech GmbH signs a joint investment agreement with b.value AG, BMH Beteiligungs-Managementgesellschaft Hessen mbH and HEAG Holding AG. Revoltech is developing an innovative and sustainable leather substitute made from purely plant-based material with the product name LOVR. The seven-figure seed investment is intended to advance the development of the operating business.

Revoltech was founded in 2021 by Lucas Fuhrmann, Julian Mushövel and Montgomery Wagner and is a spin-off from the TU Darmstadt. The company's goal is to develop and market a sustainable leather substitute with the product name LOVR. LOVR stands for "leather-like-without-plastic-vegan-residue-based." The plastic-free and purely plant-based alternative to the animal-based product not only looks like leather, but also feels like it. It is made with a unique technology using agricultural residues and purely plant-based additives. The textile is recyclable and biodegradable. Translated with www.DeepL.com/Translator (free version)

Lucas Fuhrmann had the original idea for the product after an internship at a fashion company known for its fair and green products. After realizing that much of the purported sustainability is often greenwashing, he began researching alternatives for leather that did not use chemicals or plastic. The result is LOVR, whose manufacturing process uses residual materials from hemp grown in Germany. It also requires only 0.3% of the CO2 emissions produced by conventional leather manufacturing.2"Our breakthrough technology ensures that we can produce LOVR with a minimal carbon footprint. Our material will play an important role in the fight against climate change and for the preservation of our ecosystems," affirms Julian Mushövel, Co-Founder & CTO.

The seed investment will be used to develop operations and expand production of the revolutionary textile. "The seed funding is a big step for LOVR. I am very happy that we have found partners who share and support our vision of a sustainable circular economy," says Lucas Fuhrmann, Co-Founder and CEO.  Montgomery Wagner, Co-Founder & COO, is also excited about the prospects offered by the investment: "With this seed round, we are financing our market entry. The next two years will be about making the step from lab to industry. We are pleased that b.value, BMH and HEAG are supporting us in this endeavor."

Peter Kallien, CEO of b.value AG, stated, "We are pleased to support Revoltech GmbH in its mission to revolutionize the leather market with its sustainable leather alternative LOVR, which is based on a strong and scalable technology foundation and a highly competent and enthusiastic founding team."

"LOVR has developed the first truly sustainable alternative to leather and is thus making a major contribution to a resource-conserving leather and textile industry," Helge Haase, responsible investment manager at BMH, is convinced. "We see significant growth potential as the trend towards sustainable business has reached all industries and is here to stay."

Prof. Dr. Klaus-Michael Ahrend and Dr. Markus Hoschek, members of HEAG's Management Board, look to the joint future with confidence: "One of HEAG's main goals is to support start-ups that use innovative concepts to address ecological and social challenges. With its idea of sustainable alternatives to leather, Revoltech GmbH is a perfect fit for HEAG and HEAG Gründerfonds."

About Revoltech

Revoltech GmbH develops, produces and distributes LOVR, a plastic-free and 100% plant-based alternative to leather made from hemp fibers. The company's goal is to transform the leather industry by introducing a truly sustainable material made from agricultural waste. Production is based on the principles of the circular economy and does not use chemicals. www.madewithlovr.com

About b.value

b.value AG not only invests as an early-stage investor in the fields of synthetic biology and advanced materials, but also actively supports its portfolio companies in their development with the unique "b.value Company Building" approach: The portfolio companies benefit from the high technological expertise and operational experience of the b.value team. The management team has more than 40 years of experience in founding, managing and developing technology companies and commercializing biotechnological developments. In addition, they benefit from the concentrated experience of the supervisory board and the broad network of b.value AG. www.b-value.de

About BMH

Beteiligungs-Managementgesellschaft Hessen mbH ("BMH"), based in Wiesbaden, was founded in 2001 and is a wholly owned subsidiary of Landesbank Hessen-Thüringen Girozentrale (Helaba). Through Wirtschafts- und Infrastrukturbank Hessen (WIBank), BMH Hessen is actively involved in the economic development activities of the State of Hesse. As a medium-sized investment and venture capital company, BMH bundles public investment interests and financing instruments for early-stage, growth and medium-sized companies in Hesse. BMH currently manages seven investment funds with an invested investment volume of around 125 million euros. Since its foundation, BMH has invested over 250 million euros in a total of more than 500 companies. Investment focuses include the software & IT, life sciences, mechanical and plant engineering, industrial goods, professional services and e-commerce sectors. www.bmh-hessen.de

About HEAG

HEAG is the holding and management company of the HEAG Group. It is also the investment management company of the City of Darmstadt. HEAG supports the economic participations of the City of Darmstadt and anchors the city's objectives, especially in the case of the approximately 110 majority shareholdings. HEAG is the central advisor to the city of Darmstadt in all economic matters relating to municipal companies. www.heag.de

Seed round for market entry of Revoltech GmbH's sustainable leather alternative LOVR.

Darmstadt, May 25, 2022 - Darmstadt-based startup Revoltech GmbH signs a joint investment agreement with b.value AG, BMH Beteiligungs-Managementgesellschaft Hessen mbH and HEAG Holding AG. Revoltech is developing an innovative and sustainable leather substitute made from purely plant-based material with the product name LOVR. The seven-figure seed investment is intended to advance the development of the operating business.

Revoltech was founded in 2021 by Lucas Fuhrmann, Julian Mushövel and Montgomery Wagner and is a spin-off from the TU Darmstadt. The company's goal is to develop and market a sustainable leather substitute with the product name LOVR. LOVR stands for "leather-like-without-plastic-vegan-residue-based." The plastic-free and purely plant-based alternative to the animal-based product not only looks like leather, but also feels like it. It is made with a unique technology using agricultural residues and purely plant-based additives. The textile is recyclable and biodegradable. Translated with www.DeepL.com/Translator (free version)

Lucas Fuhrmann had the original idea for the product after an internship at a fashion company known for its fair and green products. After realizing that much of the purported sustainability is often greenwashing, he began researching alternatives for leather that did not use chemicals or plastic. The result is LOVR, whose manufacturing process uses residual materials from hemp grown in Germany. It also requires only 0.3% of the CO2 emissions produced by conventional leather manufacturing.2"Our breakthrough technology ensures that we can produce LOVR with a minimal carbon footprint. Our material will play an important role in the fight against climate change and for the preservation of our ecosystems," affirms Julian Mushövel, Co-Founder & CTO.

The seed investment will be used to develop operations and expand production of the revolutionary textile. "The seed funding is a big step for LOVR. I am very happy that we have found partners who share and support our vision of a sustainable circular economy," says Lucas Fuhrmann, Co-Founder and CEO.  Montgomery Wagner, Co-Founder & COO, is also excited about the prospects offered by the investment: "With this seed round, we are financing our market entry. The next two years will be about making the step from lab to industry. We are pleased that b.value, BMH and HEAG are supporting us in this endeavor."

Peter Kallien, CEO of b.value AG, stated, "We are pleased to support Revoltech GmbH in its mission to revolutionize the leather market with its sustainable leather alternative LOVR, which is based on a strong and scalable technology foundation and a highly competent and enthusiastic founding team."

"LOVR has developed the first truly sustainable alternative to leather and is thus making a major contribution to a resource-conserving leather and textile industry," Helge Haase, responsible investment manager at BMH, is convinced. "We see significant growth potential as the trend towards sustainable business has reached all industries and is here to stay."

Prof. Dr. Klaus-Michael Ahrend and Dr. Markus Hoschek, members of HEAG's Management Board, look to the joint future with confidence: "One of HEAG's main goals is to support start-ups that use innovative concepts to address ecological and social challenges. With its idea of sustainable alternatives to leather, Revoltech GmbH is a perfect fit for HEAG and HEAG Gründerfonds."

About Revoltech

Revoltech GmbH develops, produces and distributes LOVR, a plastic-free and 100% plant-based alternative to leather made from hemp fibers. The company's goal is to transform the leather industry by introducing a truly sustainable material made from agricultural waste. Production is based on the principles of the circular economy and does not use chemicals. www.madewithlovr.com

About b.value

b.value AG not only invests as an early-stage investor in the fields of synthetic biology and advanced materials, but also actively supports its portfolio companies in their development with the unique "b.value Company Building" approach: The portfolio companies benefit from the high technological expertise and operational experience of the b.value team. The management team has more than 40 years of experience in founding, managing and developing technology companies and commercializing biotechnological developments. In addition, they benefit from the concentrated experience of the supervisory board and the broad network of b.value AG. www.b-value.de

About BMH

Beteiligungs-Managementgesellschaft Hessen mbH ("BMH"), based in Wiesbaden, was founded in 2001 and is a wholly owned subsidiary of Landesbank Hessen-Thüringen Girozentrale (Helaba). Through Wirtschafts- und Infrastrukturbank Hessen (WIBank), BMH Hessen is actively involved in the economic development activities of the State of Hesse. As a medium-sized investment and venture capital company, BMH bundles public investment interests and financing instruments for early-stage, growth and medium-sized companies in Hesse. BMH currently manages seven investment funds with an invested investment volume of around 125 million euros. Since its foundation, BMH has invested over 250 million euros in a total of more than 500 companies. Investment focuses include the software & IT, life sciences, mechanical and plant engineering, industrial goods, professional services and e-commerce sectors. www.bmh-hessen.de

About HEAG

HEAG is the holding and management company of the HEAG Group. It is also the investment management company of the City of Darmstadt. HEAG supports the economic participations of the City of Darmstadt and anchors the city's objectives, especially in the case of the approximately 110 majority shareholdings. HEAG is the central advisor to the city of Darmstadt in all economic matters relating to municipal companies. www.heag.de

05.05.2022

Actome has released the first commercial products to the EU market based on the Protein Interaction Coupling (PICO) Technology. The PICO assay kits for measuring proteins and protein interactions are available through the online webshop .

Actome GmbH is a life-science startup form Freiburg adapting digital PCR (dPCR) technology for the ultra-sensitive measurement of proteins and protein interactions. Our first products based on the Protein Interaction Coupling (PICO) Technology enable the use of the QIAcuity dPCR product line of QIAGEN for measuring proteins and protein interactions. The assay kits contain all necessary materials for labeling of antibodies with the unique PICO Labels and to prepare the assay for readout by dPCR. Registered customers can use the Actome’s AMULATOR software free of charge to analyze proteins and protein interactions with hitherto unseen performance.

Actome has released the first commercial products to the EU market based on the Protein Interaction Coupling (PICO) Technology. The PICO assay kits for measuring proteins and protein interactions are available through the online webshop .

Actome GmbH is a life-science startup form Freiburg adapting digital PCR (dPCR) technology for the ultra-sensitive measurement of proteins and protein interactions. Our first products based on the Protein Interaction Coupling (PICO) Technology enable the use of the QIAcuity dPCR product line of QIAGEN for measuring proteins and protein interactions. The assay kits contain all necessary materials for labeling of antibodies with the unique PICO Labels and to prepare the assay for readout by dPCR. Registered customers can use the Actome’s AMULATOR software free of charge to analyze proteins and protein interactions with hitherto unseen performance.

01.02.2022

Two of our portfolio companies, traceless materials and FibreCoat GmbH are among the Top 50 Start-ups 2021 in Germany.

FibreCoat could improve from rank 43 in 2020 up to rank 17 in 2021 and traceless leads the ranking. Congratulations to the founders and their teams! (further information)

Our newest portfolio member FibreCoat and its production partner Deutsche Basalt Faser GmbH (DBF) received the approval of a 1.73 mio € grant from the German state of Saxony-Anhalt to expand its production capacity at the DBF site located at Sangerhausen. (further information)

Futhermore, the Lufthansa Group announced its cooperation with the traceless materials GmbH. With help of the start-up, Lufthansa will provide sustainable packaging solutions for its on-board meals which will be fully compostable under natural conditions. (further information)

We are looking forward to futher potentially upcoming good news this week!

Two of our portfolio companies, traceless materials and FibreCoat GmbH are among the Top 50 Start-ups 2021 in Germany.

FibreCoat could improve from rank 43 in 2020 up to rank 17 in 2021 and traceless leads the ranking. Congratulations to the founders and their teams! (further information)

Our newest portfolio member FibreCoat and its production partner Deutsche Basalt Faser GmbH (DBF) received the approval of a 1.73 mio € grant from the German state of Saxony-Anhalt to expand its production capacity at the DBF site located at Sangerhausen. (further information)

Futhermore, the Lufthansa Group announced its cooperation with the traceless materials GmbH. With help of the start-up, Lufthansa will provide sustainable packaging solutions for its on-board meals which will be fully compostable under natural conditions. (further information)

We are looking forward to futher potentially upcoming good news this week!

14.01.2022

Why 3D bioprinting? Because it is the future of tissue and organ reproduction for transplantation!

How can this goal be achieved and when will there be functioning organs on demand? The article in Frankfurter Rundschau provides an overview of the current situation and the role of 3D bioprinting. Among other industry and thought leaders such as Swedish visionary Erik Gatenholm, Cellbricks with founder Dr. Lutz Kloke is mentioned as Berlin's spearhead of 3D bioprinting.

Moreover, the article demonstrates the reputation of the founders of our portfolio companies since In the same article, Dr. Peter Koltay, CEO of our Freiburg portfolio company Actome GmbH and senior scientist at the Institute for Microsystems Technology (IMTEK) at the University of Freiburg, comments on the state of development and the potential of the technology. Actome GmbH und leitender Wissenschaftler des Instituts für Mikrosystemtechnik (IMTEK) an der Universität Freiburg, ordnet im gleichen Artikel den Entwicklungsstand und die Potenziale der Technologie als Experte ein.

Frankfurter Rundschau article.

Why 3D bioprinting? Because it is the future of tissue and organ reproduction for transplantation!

How can this goal be achieved and when will there be functioning organs on demand? The article in Frankfurter Rundschau provides an overview of the current situation and the role of 3D bioprinting. Among other industry and thought leaders such as Swedish visionary Erik Gatenholm, Cellbricks with founder Dr. Lutz Kloke is mentioned as Berlin's spearhead of 3D bioprinting.

Moreover, the article demonstrates the reputation of the founders of our portfolio companies since In the same article, Dr. Peter Koltay, CEO of our Freiburg portfolio company Actome GmbH and senior scientist at the Institute for Microsystems Technology (IMTEK) at the University of Freiburg, comments on the state of development and the potential of the technology. Actome GmbH und leitender Wissenschaftler des Instituts für Mikrosystemtechnik (IMTEK) an der Universität Freiburg, ordnet im gleichen Artikel den Entwicklungsstand und die Potenziale der Technologie als Experte ein.

Frankfurter Rundschau article.

10.01.2022

SenseUp has been awarded a grant by the Federal Ministry of Education and Research (BMBF), for SenseUp to apply their platform technology to the production of pharmaceutical proteins and peptides. The grant provides SenseUp with 2,1 million € non-dilutive funding and will be used to further develop and scale-up their bio-production platform for pharmaceutical proteins and peptides in the next 5 years.

The funding was provided as part of the project "ModellRegion, BioRevierPLUS: BioökonomieREVIER ". With this project, the BMBF is funding a wide variety of promising research, development, and innovation projects (R&D&I) in the field of the bioeconomy in the Rheinischen Revier as part of the National Bioeconomy Strategy and the Structural Strengthening of Coal Regions Act.

SenseUp sees this funding success as a confirmation of their bio-production strategy and the great potential of bio-manufacturing determining what we eat, what cures us, the products we put on our skin, and the way we build our physical world in the coming decades. The company will play a key role in this transformation by enabling efficient bio-production platforms with crucial cost- and scaling-advantages using its disruptive natural evolution technology.

"SenseUp has a unique advantage here'' says Dr. Georg Schaumann, CEO and founder of the company, ''we have already developed groundbreaking bio-production processes for fine chemicals using our unique natural evolution technology. With this grant, we will now be able to do the same for pharmaceutical proteins and peptides."

About SenseUp Biotechnology GmbH
Founded in 2015, SenseUp develops microbial production strains and processes for large-scale production of e.g. amino acids under a licensing model. Compared to conventional optimization strategies, the patented SenseUp technology allows for 50,000 times faster selection of optimized production strains under relevant process conditions and thus enables customized and process-specific development of ready-to-use and optionally GMO-free high-performance production organisms. Especially for food and feed applications, these are important advantages for SenseUp customers. Extending the product-spectrum to RNA and proteins/peptides, SenseUp additionally focusses on markets for pharmaceuticals, animal-free consumer products and biopesticides.

SenseUp has been awarded a grant by the Federal Ministry of Education and Research (BMBF), for SenseUp to apply their platform technology to the production of pharmaceutical proteins and peptides. The grant provides SenseUp with 2,1 million € non-dilutive funding and will be used to further develop and scale-up their bio-production platform for pharmaceutical proteins and peptides in the next 5 years.

The funding was provided as part of the project "ModellRegion, BioRevierPLUS: BioökonomieREVIER ". With this project, the BMBF is funding a wide variety of promising research, development, and innovation projects (R&D&I) in the field of the bioeconomy in the Rheinischen Revier as part of the National Bioeconomy Strategy and the Structural Strengthening of Coal Regions Act.

SenseUp sees this funding success as a confirmation of their bio-production strategy and the great potential of bio-manufacturing determining what we eat, what cures us, the products we put on our skin, and the way we build our physical world in the coming decades. The company will play a key role in this transformation by enabling efficient bio-production platforms with crucial cost- and scaling-advantages using its disruptive natural evolution technology.

"SenseUp has a unique advantage here'' says Dr. Georg Schaumann, CEO and founder of the company, ''we have already developed groundbreaking bio-production processes for fine chemicals using our unique natural evolution technology. With this grant, we will now be able to do the same for pharmaceutical proteins and peptides."

About SenseUp Biotechnology GmbH
Founded in 2015, SenseUp develops microbial production strains and processes for large-scale production of e.g. amino acids under a licensing model. Compared to conventional optimization strategies, the patented SenseUp technology allows for 50,000 times faster selection of optimized production strains under relevant process conditions and thus enables customized and process-specific development of ready-to-use and optionally GMO-free high-performance production organisms. Especially for food and feed applications, these are important advantages for SenseUp customers. Extending the product-spectrum to RNA and proteins/peptides, SenseUp additionally focusses on markets for pharmaceuticals, animal-free consumer products and biopesticides.

07.01.2022

Actome and QIAGEN have signed a licensing and co-marketing agreement to jointly accelerate the commercialization of Actome’s proprietary Protein-Interaction-Coupling (PICO) -Technology

Actome GmbH, a life-science start-up company from the University of Freiburg and Hahn-Schickard, Germany has signed a license agreement and a co-marketing agreement with QIAGEN GmbH, Hilden, Germany, to jointly accelerate the market entry of Actome’s Protein-Interaction-Coupling (PICO) - Technology. The collaboration will help Actome to bring products to the market faster while providing a unique innovative feature to the QIAcuity dPCR product line of QIAGEN. Actome will market first products exclusively for use on QIAGEN’s digital PCR instruments as well as support QIAGEN in developing own products. Both partners will jointly commercialize the disruptive PICO-Technology for molecular biological research in the future.

The unique performance of Actome’s products is based on the patented PICO -Technology that detects single protein molecules and protein interaction complexes by translating protein status into DNA- barcodes. These barcodes are then detected by the method of digital PCR and decoded by a proprietary software developed by Actome. “Our PICO-Technology expands the capabilities of the QIAcuity digital PCR platform by QIAGEN from nucleic acids to proteins. The application of our technology in the fields of proteomics, molecular pathway research and biomarker discovery will help to increase our knowledge about molecular biological processes and will transform molecular biological research in an unprecedented way.” says Csaba Jeney, co-founder, CEO, and inventor of the technology.

Proteins control and direct biological processes through their interactions, the so-called interactome, by which they determine our health and wellbeing. Tools to study the interactome enable the understanding of cellular processes and open up an enormous potential for research, diagnostics and therapies. Tackling these challenges, Actome's innovative technology is a breakthrough that will revolutionize research and biomedicine. “QIAcuity is expanding into new research fields as a cost-effective and very reliable digital PCR system,” said Thomas Schweins, Senior Vice President, Head of the Life Science Business Area at QIAGEN. “The partnership with Actome extends the use of this technology to protein quantification and protein-protein interaction.”

Actome GmbH is a privately held young life-science startup founded in 2017. The year before Dr. Jeney moved from Budapest to Freiburg to partner with Dr. Koltay and to leverage his start-up experience and the excellent environment provided by the University of Freiburg and the Hahn-Schickard research institute in Freiburg. Actome provides assay kits, bioinformatics software and services for the sensitive, highly parallel and quantitative measurement of proteins and protein interactions. The long term vision of Actome is to decode the whole interactome and to exploit these discoveries in molecular diagnostic products for personalized medicine. Actome’s first products will target the research market in the field of molecular biology with a specific focus on assay-kits for multi-omics and single cell analysis.

www.actome.de

QIAGEN press release

Actome and QIAGEN have signed a licensing and co-marketing agreement to jointly accelerate the commercialization of Actome’s proprietary Protein-Interaction-Coupling (PICO) -Technology

Actome GmbH, a life-science start-up company from the University of Freiburg and Hahn-Schickard, Germany has signed a license agreement and a co-marketing agreement with QIAGEN GmbH, Hilden, Germany, to jointly accelerate the market entry of Actome’s Protein-Interaction-Coupling (PICO) - Technology. The collaboration will help Actome to bring products to the market faster while providing a unique innovative feature to the QIAcuity dPCR product line of QIAGEN. Actome will market first products exclusively for use on QIAGEN’s digital PCR instruments as well as support QIAGEN in developing own products. Both partners will jointly commercialize the disruptive PICO-Technology for molecular biological research in the future.

The unique performance of Actome’s products is based on the patented PICO -Technology that detects single protein molecules and protein interaction complexes by translating protein status into DNA- barcodes. These barcodes are then detected by the method of digital PCR and decoded by a proprietary software developed by Actome. “Our PICO-Technology expands the capabilities of the QIAcuity digital PCR platform by QIAGEN from nucleic acids to proteins. The application of our technology in the fields of proteomics, molecular pathway research and biomarker discovery will help to increase our knowledge about molecular biological processes and will transform molecular biological research in an unprecedented way.” says Csaba Jeney, co-founder, CEO, and inventor of the technology.

Proteins control and direct biological processes through their interactions, the so-called interactome, by which they determine our health and wellbeing. Tools to study the interactome enable the understanding of cellular processes and open up an enormous potential for research, diagnostics and therapies. Tackling these challenges, Actome's innovative technology is a breakthrough that will revolutionize research and biomedicine. “QIAcuity is expanding into new research fields as a cost-effective and very reliable digital PCR system,” said Thomas Schweins, Senior Vice President, Head of the Life Science Business Area at QIAGEN. “The partnership with Actome extends the use of this technology to protein quantification and protein-protein interaction.”

Actome GmbH is a privately held young life-science startup founded in 2017. The year before Dr. Jeney moved from Budapest to Freiburg to partner with Dr. Koltay and to leverage his start-up experience and the excellent environment provided by the University of Freiburg and the Hahn-Schickard research institute in Freiburg. Actome provides assay kits, bioinformatics software and services for the sensitive, highly parallel and quantitative measurement of proteins and protein interactions. The long term vision of Actome is to decode the whole interactome and to exploit these discoveries in molecular diagnostic products for personalized medicine. Actome’s first products will target the research market in the field of molecular biology with a specific focus on assay-kits for multi-omics and single cell analysis.

www.actome.de

QIAGEN press release

Contact

b.value AG

Otto-Hahn-Straße 15

D-44227 Dortmund

+49 (0) 231/79300196

 

info@b-value.de

  • Opens in a new tab

Contact Person

Dr. Georg Lentzen (Managing Director)

Georg.Lentzen@b-value.de

 

Peter Kallien (Managing Director)

Peter.Kallien@b-value.de

Contact

b.value AG

Otto-Hahn-Straße 15

D-44227 Dortmund

 

+49 (0) 231/79300196

Impact by Deep Tech

Copyright 2023 b.value AG